Verrica Pharmaceuticals I... (VRCA)
NASDAQ: VRCA
· Real-Time Price · USD
5.91
-0.24 (-3.90%)
At close: Aug 15, 2025, 3:01 PM
Verrica Pharmaceuticals Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | 204K | -9.74M | -16.2M | -22.86M | -17.19M | -20.33M | -24.61M | -24.8M | -10.99M | -6.59M | -5.93M | 83K | -10.17M | -8.47M | -9.54M | -12.83M | -11.78M | -936K |
Depreciation & Amortization | 118K | 208K | 253K | 342K | 334K | 340K | 217K | 353K | 135K | 202K | 395K | 127K | 98K | 98K | 370K | 111K | 37K | 11K |
Stock-Based Compensation | 888K | 1.03M | 756K | 2.11M | 2.23M | 2.07M | 2.08M | 9.66M | 1.54M | 1.09M | 1.17M | 1.41M | 1.08M | 1.32M | 1.32M | 1.48M | 1.85M | 1.4M |
Other Working Capital | -767K | 1.44M | -4.88M | 912K | 1.61M | 614K | 4.63M | 3.5M | 3.08M | 258K | -786K | -299K | 1.2M | -1.38M | -1.07M | 161K | 12.1M | -12.22M |
Other Non-Cash Items | 353K | 417K | 3.22M | 832K | 657K | 483K | 5.32M | -1.23M | -594K | n/a | -172K | -248K | 418K | 409K | 361K | 352K | 336K | 393K |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | -2.15M | 1.48M | 666K | n/a | n/a | n/a | n/a | n/a | -118K | 96K | 46K | 42K |
Change in Working Capital | -11.61M | -4.59M | -4.09M | 11.02M | -2.39M | -2.51M | 4.64M | -281K | 4.57M | 703K | -416K | -1.08M | 1.39M | -1.69M | -1.09M | 248K | 12.01M | -11.7M |
Operating Cash Flow | -10.04M | -12.68M | -16.06M | -8.56M | -16.36M | -19.95M | -14.51M | -14.81M | -4.67M | -4.59M | -4.95M | 1.82M | -7.18M | -8.34M | -8.7M | -10.6M | 2.5M | -10.79M |
Capital Expenditures | n/a | n/a | n/a | -16K | -11K | n/a | -227K | -65K | -59K | -11K | -66K | -77K | -154K | -5K | -237K | -39K | -296K | -311K |
Cash Acquisitions | n/a | n/a | 8K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -8K | 8K | -4.49M | -9.83M | -12.87M | -36.93M | -9.29M |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 7M | 2.01M | 2.49M | 47.51M | 14.2M | 19.2M | 15.1M | 20.5M |
Other Investing Acitivies | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -180K | 2.15M | -141K | -5K | -124K | 6.33M | -8K | -69K |
Investing Cash Flow | n/a | n/a | 8K | -16K | -11K | n/a | -227K | -65K | -59K | -11K | 6.75M | 2.07M | 2.21M | 43.01M | 4.01M | 6.29M | -22.14M | 10.84M |
Debt Repayment | -4.16M | -4.06M | -1.51M | -234K | -177K | -665K | -23K | 44.1M | n/a | n/a | -43.75M | -43.75M | -1K | -1K | -2K | -2K | n/a | 4.97M |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | -1K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | n/a | n/a | 1.3M | n/a | -613K | n/a | -3K | n/a | n/a | -21K | 43.75M | n/a | n/a | -17K | n/a | 45K | 241K | 240K |
Financial Cash Flow | -4.16M | -4.06M | 39.43M | -397K | -640K | -661K | -27K | 44.04M | -84K | 30.28M | -87.5M | -16.85M | -1K | -18K | -3K | 43K | 241K | 33.37M |
Net Cash Flow | -14.2M | -16.73M | 23.37M | -8.97M | -17.01M | -20.61M | -14.76M | 29.17M | -4.81M | 25.68M | 1.8M | -12.96M | -4.98M | 34.66M | -4.69M | -4.26M | -19.39M | 33.41M |
Free Cash Flow | -10.04M | -12.68M | -16.06M | -8.57M | -16.37M | -19.95M | -14.96M | -14.88M | -4.73M | -4.6M | -5.02M | 1.75M | -7.33M | -8.35M | -8.94M | -10.64M | 2.2M | -11.1M |